Incyte Corporation (INCY)

90.14
0.20 0.22
NASDAQ
Prev Close 89.94
Open 86.62
Day Low/High 86.50 / 91.11
52 Wk Low/High 62.48 / 110.36
Volume 1.39M
Exchange NASDAQ
Shares Outstanding 218.70B
Market Cap 19.67B
P/E Ratio N/A
Div & Yield N.A. (N.A)
Jim Cramer Discusses Syria Missile Strikes, Jobs Report, Oil and Comcast's Mobile Service

Jim Cramer Discusses Syria Missile Strikes, Jobs Report, Oil and Comcast's Mobile Service

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer reacts to the Syria missile strikes and the weaker-than-expected March jobs report.

Cramer: Retail Rally Shows the Perils of Being Too Negative

Cramer: Retail Rally Shows the Perils of Being Too Negative

There's a forest fire in the sector.

Takeaways and Observations: Second Quarter Start

"I would say that (today) the averages are faring better than the average stock -- on average. If you know what I mean!" --  Kass Diary, Consider this Yogiism!   With opening day yesterday and tonite's NCAA final (I like North Carolina in a high sin...

Cramer: Stay the Course, but Keep Cash Handy

Cramer: Stay the Course, but Keep Cash Handy

It's pretty normal to have profit-taking after such a strong first quarter.

I'm Big on Housing Entering Quarter No. 2

I'm Big on Housing Entering Quarter No. 2

Home builders make up the second-largest allocation in my portfolio, behind biotech.

Incyte Likely to Incite Further Gains

Incyte Likely to Incite Further Gains

Approach the long side of this great biopharma play on any shallow dip in price, like one or two dollars.

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

4 Biotech Stocks on the Move

4 Biotech Stocks on the Move

These four biotech stocks have been moving on some interesting news and clinical results.

Softness in Incyte Should Be Short-Lived, if Our Quants Are Right

Softness in Incyte Should Be Short-Lived, if Our Quants Are Right

A trade at $126 will be a new high for the move up.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Get Excited About Incyte

Get Excited About Incyte

Prices have marched their way all the way back up to the bottom end of key resistance.

Jim Jubak’s Four Favorite Stocks for Volatile Times

Jim Jubak’s Four Favorite Stocks for Volatile Times

Investors should try and profit from the market’s volatility, not run away from it, said Jim Jubak, author of Juggling With Knives.

4 Great Stock-ing Stuffers for 2016

4 Great Stock-ing Stuffers for 2016

These biotech/pharma picks could give you a very happy new year.

Put Health Care Stocks on Shopping List

Put Health Care Stocks on Shopping List

Have it ready in case market turns volatile.

A Trio of Healthcare Plays

A Trio of Healthcare Plays

Here's how I'd trade this biotech fund, Incyte and Immunogen.

My Stock Menagerie

My Stock Menagerie

A group of names breaking out today.

Incyte Corp numbers lowered at Jefferies

Incyte upgraded at Lazard

Incyte Corp upgraded at Goldman

The Next Big Thing in Biotech: Pfizer

The Next Big Thing in Biotech: Pfizer

Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.

Passing the Test

Passing the Test

These three stocks have re-established the importance of a prior technical level and are in position to move higher off this support.

Incyte downgraded at Morgan Stanley

Incyte downgraded at Citi

Incyte estimates, target raised at JMP